Nilay Shah

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Nilay Shah

Biography

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Research

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Nilay Shah

Biography

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Research

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Nilay Shah

Contact Information

• Call us at:
• (614) 722-3550
• Fax us at:
• (614) 722-3369
• PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Nilay Shah

Biography

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

Biography

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

Biography

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

        Dr. Nilay Shah is a physician scientist in the Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital. He also has a joint appointment as Assistant Professor in the Department of Pediatrics at The Ohio State

University College of Medicine. His research focuses on embryonic cancers, including neuroblastoma and pediatric sarcomas. He specifically examines how these types of childhood cancers avoid normal development and become cancers. His goal is to identify signaling pathways as biomarkers for diagnosis and treatment. He also examines the functions of long noncoding RNAs in these diseases and how they can be modulated to affect disease response. He collaborates with the Department of Neuroscience at OSU to use zebrafish as a disease model. Dr. Shah is a graduate of the Honors Program in Medical Education at Northwestern University, earning his medical degree in 2003. Dr. Shah completed a residency in General Pediatrics in 2006 at the Children’s Hospital of Wisconsin, and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins University and the National Cancer Institute in 2011. He also was a Research Instructor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C., prior to his arrival at Nationwide Children’s Hospital. In addition to his research, Dr. Shah sees pediatric oncology patients through the Division of Pediatric Hematology/Oncology at Nationwide Children’s Hospital.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

• Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Hematology/Oncology & BMT

Physician Team

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

• Hematology/Oncology & BMT
• Physician Team
• Hematology, Oncology and BMT Fellowship
• Faculty
• Primary Department
• Pediatrics
• Primary Section
• Hematology & Oncology

Research

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

Research

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

Research

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

                  Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.

                


                  Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.

                


                  Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.

                


                  Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.

                


                  Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64: 

                


                  Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64: 

                


                  Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

View More Publications

• Perisa MP, Storey M, Streby KA, Ranalli MA, Skeens M, Shah N. Cabozantinib for relapsed neuroblastoma: Single institution case series. Pediatr Blood Cancer. 2020 Jul; 67: e28317.
• Shah N, Scharschmidt T, Fung B, Conces M, Setty BA. Aneursymal Bone Cyst: An Uncommon Paraspinal Tumor in Children. J Pediatr Hematol Oncol. 2019 Mar; 41: e129-e131.
• Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia. 2018 Oct; 20: 965-974.
• Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis. 2018 Feb 14; 9: 220.
• Wedekind MF, Ranalli M, Shah N. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma. Pediatr Blood Cancer. 2017 Nov; 64:
• Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017 Aug; 64:
• Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese T, Chang HY, Pandita TK, Sukumar S. HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res. 2016 Aug 1; 76: 4443-56.

Education

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Education

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Education

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

Date of Appointment at Nationwide Children’s Hospital: 09/27/2013

Board Certifications

Pediatric Hematology Oncology

Fellowship

John Hopkins Hospital

Date Completed: 06/30/2011

Fellowship

National Cancer Institute

Date Completed: 06/30/2009

Residency

Children’s Hospital of Wisconsin

Date Completed: 06/30/2006

Medical School

Northwestern University

Date Completed: 06/20/2003

• Pediatric Hematology Oncology

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

• Call us at:
• (614) 722-3550
• Fax us at:
• (614) 722-3369
• Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)